Status:
RECRUITING
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
Lead Sponsor:
ARTIDIS AG
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This prospective, blinded, single-arm study aims to test the performance of nanomechanical phenotype in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response compared to the ...
Detailed Description
Objective: To test the performance of nanomechanical phenotype tests in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response, compared to the gold standard of histopathologi...
Eligibility Criteria
Inclusion
- Patients aged ≥ 18 years
- Ability to understand and the willingness to sign a written informed consent.
- Indication for breast biopsy for diagnostic purposes
- ECOG performance status of 0 to 3.
Exclusion
- Conditions that, in the investigator's opinion, might indicate that the subject is not suitable for the study.
Key Trial Info
Start Date :
November 2 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2035
Estimated Enrollment :
2706 Patients enrolled
Trial Details
Trial ID
NCT06085833
Start Date
November 2 2023
End Date
November 1 2035
Last Update
September 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baylor College of Medicine
Houston, Texas, United States, 77030